Quick Answer
Monopar Therapeutics reported Common Stock Shares Outstanding of 6.69 million shares for the year ending 2025.
- Monopar Therapeutics showed an increase of +9.7% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Monopar Therapeutics's annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: 9.29 million shares | Q2 2018: 9.29 million shares | Q3 2018: 9.29 million shares | Q1 2019: 9.29 million shares | Q2 2019: 9.29 million shares | Q3 2019: 9.29 million shares | Q1 2020: 10.62 million shares | Q2 2020: 10.74 million shares | Q3 2020: 11.45 million shares | Q1 2021: 12.57 million shares | Q2 2021: 12.58 million shares | Q3 2021: 12.59 million shares | Q1 2022: 12.62 million shares | Q2 2022: 12.70 million shares | Q3 2022: 12.86 million shares | Q1 2023: 13.22 million shares | Q2 2023: 13.90 million shares | Q3 2023: 14.20 million shares | Q1 2024: 17.48 million shares | Q2 2024: 17.60 million shares | Q3 2024: 3.53 million shares | Q1 2025: 6.12 million shares | Q2 2025: 6.13 million shares | Q3 2025: 6.66 million shares.
- Historical annual values: Fiscal year 2025: 6.69 million shares | Fiscal year 2024: 6.10 million shares | Fiscal year 2023: 2.98 million shares | Fiscal year 2022: 12.95 million shares | Fiscal year 2021: 12.60 million shares | Fiscal year 2020: 11.45 million shares | Fiscal year 2019: 10.59 million shares | Fiscal year 2018: 9.29 million shares | Fiscal year 2017: 9.29 million shares | Fiscal year 2016: 0 shares.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: